These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20411957)

  • 1. Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation.
    Yim CB; Dijkgraaf I; Merkx R; Versluis C; Eek A; Mulder GE; Rijkers DT; Boerman OC; Liskamp RM
    J Med Chem; 2010 May; 53(10):3944-53. PubMed ID: 20411957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spacer effects on in vivo properties of DOTA-conjugated dimeric [Tyr3]octreotate peptides synthesized by a "Cu(I)-click" and "sulfo-click" ligation method.
    Yim CB; van der Wildt B; Dijkgraaf I; Joosten L; Eek A; Versluis C; Rijkers DT; Boerman OC; Liskamp RM
    Chembiochem; 2011 Mar; 12(5):750-60. PubMed ID: 21328514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers.
    Yim CB; Boerman OC; de Visser M; de Jong M; Dechesne AC; Rijkers DT; Liskamp RM
    Bioconjug Chem; 2009 Jul; 20(7):1323-31. PubMed ID: 19537708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.
    Dijkgraaf I; Rijnders AY; Soede A; Dechesne AC; van Esse GW; Brouwer AJ; Corstens FH; Boerman OC; Rijkers DT; Liskamp RM
    Org Biomol Chem; 2007 Mar; 5(6):935-44. PubMed ID: 17340009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging.
    Orocio-Rodríguez E; Ferro-Flores G; Santos-Cuevas CL; Ramírez Fde M; Ocampo-García BE; Azorín-Vega E; Sánchez-García FM
    J Nanosci Nanotechnol; 2015 Jun; 15(6):4159-69. PubMed ID: 26369025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
    Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
    Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
    J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological evaluation of avidin-based tumor pretargeting with DOTA-Triazole-Biotin constructed via versatile Cu(I) catalyzed click chemistry.
    Uppal JK; Varshney R; Hazari PP; Chuttani K; Kaushik NK; Mishra AK
    J Drug Target; 2011 Jul; 19(6):418-26. PubMed ID: 20678008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
    Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.
    Schottelius M; Wester HJ; Reubi JC; Senekowitsch-Schmidtke R; Schwaiger M
    Bioconjug Chem; 2002; 13(5):1021-30. PubMed ID: 12236784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
    Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
    Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
    Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
    Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
    Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
    Albert R; Smith-Jones P; Stolz B; Simeon C; Knecht H; Bruns C; Pless J
    Bioorg Med Chem Lett; 1998 May; 8(10):1207-10. PubMed ID: 9871736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.